Key Highlights

  • Consensus EPS of 0.12 compares with diluted EPS of 0.03 for the second quarter, equal to 0.03 last year.
  • Consensus revenue of USD 275.35 million compares with revenues of USD 266.8 million reported, against USD 222.9 million.
  • Nuclear & Safety segment revenues were USD 186.2 million against USD 141.7 million, while Medical revenues were USD 80.6 million.
  • Corporate SG&A expenses were USD 21.3 million against USD 17.6 million, on stock compensation costs.

Mirion Technologies (NYSE:MIR) reports third-quarter results on Tuesday, Oct. 27, after the market closes. Consensus stands at EPS of 0.12 on revenue of USD 275.35 million, and the company has a market capitalization of USD 3.72 billion.

Mirion Technologies reports two segments, Nuclear & Safety and Medical. In the second quarter, it reported revenues of USD 266.8 million against USD 222.9 million and gross profit of USD 133.1 million against USD 102.5 million.

Estimates Against the Last Reported Quarter

The revenue estimate of USD 275.35 million is above the USD 266.8 million reported for the second quarter. The EPS estimate of 0.12 is above the diluted EPS of 0.03 reported, which matched the 0.03 of a year earlier.

Operating income was USD 17.9 million against USD 9.9 million, and income before taxes was USD 11.3 million against USD 7.8 million. Net income was USD 7.7 million against USD 8.3 million, and basic EPS was 0.03 against 0.04.

Segment Revenue Changes

Revenues rose USD 43.9 million. Nuclear & Safety contributed USD 186.2 million against USD 141.7 million, which the filing ties to price increases, organic volume growth, foreign exchange impacts and recent acquisitions.

Medical contributed USD 80.6 million against USD 81.2 million, and the filing attributes the decrease to lower volume.

Costs and Corporate Expenses

Cost of revenue was USD 133.7 million against USD 120.4 million, and operating expenses were USD 115.2 million against USD 92.6 million.

Corporate SG&A expenses were USD 21.3 million against USD 17.6 million, an increase of USD 3.7 million that the filing ties primarily to stock compensation costs, including expense for performance stock options granted during the quarter. Corporate and other costs were USD 22.9 million against USD 20.0 million, an increase of USD 2.9 million, with stock compensation costs of USD 2.7 million cited in the filing.

For the six months, corporate SG&A expenses were USD 44.5 million against USD 35.3 million, and corporate and other costs were USD 47.9 million against USD 39.7 million. The estimates table lists a market capitalization of USD 3.72 billion, against total assets of USD 3,521.0 million.

Selling, general and administrative expense was USD 105.1 million against USD 82.6 million, and research and development expense was USD 10.1 million against USD 10.0 million. Interest expense was USD 8.4 million against USD 11.8 million, and interest income was USD 2.6 million against USD 2.0 million.

Cash and cash equivalents were USD 418.7 million at June 30, 2026, against USD 412.3 million at the prior year-end, and total assets were USD 3,521.0 million against USD 3,588.1 million.

Comparisons to Make in the Report

Diluted EPS against 0.12 and revenue against USD 275.35 million are the headline comparisons. Other markers are Nuclear & Safety revenue against USD 186.2 million, Medical revenue and corporate SG&A expenses.